Heart type fatty acid binding protein response and subsequent development of atherosclerosis in insulin resistant polycystic ovary syndrome patients

Journal of Ovarian Research

Tuncay Delibasi³  Taner Demirci³  Zeynep Ginis²  Askin Gungunes³  Erman Cakal³  Mustafa Sahin³  Mustafa Ozbek¹  Evrim Cakir³ 

[1] Yeni Ziraat mahallesi, 660. sokak, Kanarya Apt. no : 10/ 4, TR-06200, Altındağ, Ankara, Turkey;Department of Biochemistry, Diskapi Training and Research Hospital, Ankara, Turkey;Department of Endocrinology and Metabolic Diseases, Diskapi Training and Research Hospital, Ankara, Turkey

关键词: Cardiovascular disease risk;    Insulin resistance;    Carotid intima media thickness;    Heart type free fatty acid binding protein;    Polycystic ovary syndrome;   

Others  :  814055
DOI  :  10.1186/1757-2215-5-45

 received in 2012-11-15, accepted in 2012-12-08,  发布年份 2012

【 摘 要 】

Background

Women with polycystic ovary syndrome (PCOS) have higher risk for cardiovascular disease (CVD). Heart type fatty acid binding protein (HFABP) has been found to be predictive for myocardial ischemia.Wet ested whether HFABP is the predictor for CVD in PCOS patients, who have an increased risk of cardiovascular disease.

Methods

This was a prospective, cross sectional controlled study conducted in a training and research hospital.The study population consisted of 46 reproductive-age PCOS women and 28 control subjects. We evaluated anthropometric and metabolic parameters, carotid intima media thickness and HFABP levels in both PCOS patients and control group.

Results

Mean fasting insulin, homeostasis model assessment insulin resistance index (HOMA-IR), triglyceride, total cholesterol, low density lipoprotein cholesterol, free testosterone, total testosterone, carotid intima media thickness (CIMT) levels were significantly higher in PCOS patients. Although HFABP levels were higher in PCOS patients, the difference did not reach statistically significant in early age groups. After adjustment for age and body mass index, HFABP level was positive correlated with hsCRP, free testosterone levels, CIMT and HOMA-IR.

Conclusions

Heart type free fatty acid binding protein appeared to have an important role in metabolic response and subsequent development of atherosclerosis in insulin resistant, hyperandrogenemic PCOS patients.

【 授权许可】

   
2012 Cakir et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Norman RJ, Dewailly D, Legro RS, Hickey TE: Polycystic ovary syndrome. Lancet 2007, 370:685-697.
• [2]Pasquali R, Gambineri A, Pagotto U: The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006, 113:1148-1159.
• [3]Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G, Colao A: The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case–control study. J Clin Endocrinol Metab 2004, 89:3696-3701.
• [4]Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001, 86:2453-2455.
• [5]Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM: Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:742-746.
• [6]Escobar-Morreale HF, Luque-Ramirez M, San Millan JL: The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005, 26:251-282.
• [7]Legro RS: Polycystic ovary syndrome and cardiovascular disease, 2003 a premature association? Endocr Rev 24:302-312.
• [8]Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp JH, van der Vusse GJ, Reneman RS: Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta 1988, 961:148-152.
• [9]Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS: Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
• [10]Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS: Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543.
• [11]Akbal E, Ozbek M, Gunes F, Akyurek O, Ureten K, Delibasi T: Serum heart type fatty acid binding protein levels in metabolic syndrome. Endocrine 2009, 36:433-437.
• [12]Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25.
• [13]Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21:1440-1447.
• [14]Kilic T, Ural E, Oner G, Sahin T, Kilic M, Yavuz S, Kanko M, Kahraman G, Bildirici U, Berki KT, Ural D: [Which cut-off value of high sensitivity C- reactive protein is more valuable for determining long- term prognosis in patients with acute coronary syndrome?]. Anadolu Kardiyol Derg 2009, 9:280-289.
• [15]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
• [16]Gokcel A, Ozsahin AK, Sezgin N, Karakose H, Ertorer ME, Akbaba M, Baklaci N, Sengul A, Guvener N: High prevalence of diabetes in Adana, a southern province of Turkey. Diabetes Care 2003, 26:3031-3034.
• [17]Victor VM, Rocha M, Banuls C, Alvarez A, de Pablo C, Sanchez-Serrano M, Gomez M, Hernandez-Mijares A: Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab 2011, 96:3115-3122.
• [18]Zschiesche W, Kleine AH, Spitzer E, Veerkamp JH, Glatz JF: Histochemical localization of heart-type fatty-acid binding protein in human and murine tissues. Histochem Cell Biol 1995, 103:147-156.
• [19]Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH: Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992, 288(Pt 1):285-290.
• [20]Pelsers MM, Hanhoff T, Van der Voort D, Arts B, Peters M, Ponds R, Honig A, Rudzinski W, Spener F, de Kruijk JR, Twijnstra A, Hermens WT, Menheere PP, Glatz JF: Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem 2004, 50:1568-1575.
• [21]Glatz JF, van der Vusse GJ: Cellular fatty acid-binding proteins: their function and physiological significance. Prog Lipid Res 1996, 35:243-282.
• [22]Wolfrum C, Borrmann CM, Borchers T, Spener F: Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A 2001, 98:2323-2328.
• [23]Glatz JF, Storch J: Unravelling the significance of cellular fatty acid-binding proteins. Curr Opin Lipidol 2001, 12:267-274.
• [24]Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K: Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem 1991, 24:195-201.
• [25]Azzazy HM, Pelsers MM, Christenson RH: Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem 2006, 52:19-29.
• [26]Piper HM, Schwartz P, Spahr R, Hutter JF, Spieckermann PG: Early enzyme release from myocardial cells is not due to irreversible cell damage. J Mol Cell Cardiol 1984, 16:385-388.
• [27]Viswanathan K, Kilcullen N, Morrell C, Thistlethwaite SJ, Sivananthan MU, Hassan TB, Barth JH, Hall AS: Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol 2010, 55:2590-2598.
• [28]Erlikh AD, Katrukha AG, Trifonov IR, Bereznikova AV, Gratsianskii NA: [Prognostic significance of heart fatty acid binding protein in patients with non-ST elevation acute coronary syndrome: results of follow-up for twelve months]. Kardiologiia 2005, 45:13-21.
• [29]Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS: Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413.
• [30]Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, Hotamisligil GS: Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002, 22:1686-1691.
• [31]Lam DC, Xu A, Lam KS, Lam B, Lam JC, Lui MM, Ip MS: Serum adipocyte-fatty acid binding protein level is elevated in severe OSA and correlates with insulin resistance. Eur Respir J 2009, 33:346-351.
• [32]Yun KE, Kim SM, Choi KM, Park HS: Association between adipocyte fatty acid-binding protein levels and childhood obesity in Korean children. Metabolism 2009, 58:798-802.
• [33]Ozdemir L, Elonu OH, Gocmen AY: Heart type fatty acid binding protein is more sensitive than troponin I and creatine kinase myocardial band at early stage in determining myocardial injury caused by percutaneous coronary intervention. Int Heart J 2011, 52:143-145.
• [34]McMahon CG, Lamont JV, Curtin E, McConnell RI, Crockard M, Kurth MJ, Crean P, Fitzgerald SP: 2012 Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med 2012, 30(2):267-274.
• [35]Ozbek M, Erdogan M, Dogan M, Akbal E, Ozturk MA, Ureten K: Serum Heart-Type Fatty Acid Binding Protein (H-FABP) levels in acromegaly patients. J Endocrinol Invest 2011, 34;8:576-579.
• [36]Yan GT, Lin J, Hao XH, Xue H, Zhang K, Wang LH: Heart-type fatty acid-binding protein is a useful marker for organ dysfunction and leptin alleviates sepsis-induced organ injuries by restraining its tissue levels. Eur J Pharmacol 2009, 616:244-250.